Online First

New anti-IL-23p19 inscribes its name on the plaque

Presented By

Dr Furen Zhang, Shandong Academy of Medical Science, China

Trial

Phase 2

Conference

AAD 2025

Type

News article

12 March 2025 11:32

Ivarmacitinib stimulates hair regrowth in severe alopecia areata

Presented By

Prof. Jianzhong Zhang, Peking University People’s Hospital, China

Conference

AAD 2025

Type

News article

12 March 2025 11:29

Dalgocitinib gets the upper hand in CHE

Presented By

Prof. April Armstrong, University of California, Los Angeles, USA

Trial

DELTA 1 and 2

Conference

AAD 2025

Type

News article

12 March 2025 11:28

Dupilumab in bullous pemphigoid

Presented By

Frédéric Caux, Avicenne Hospital, France

Trial

LIBERTY-BP ADEPT

Conference

AAD 2025

Type

News article

12 March 2025 11:26

Briquilimab breaks walls in CSU

Presented By

Prof. Martin Metz, Charité Universitätsmedizin, Germany

Trial

Phase 1/2, BEACON

Conference

AAD 2025

Type

News article

12 March 2025 11:25

Orelabrutinib highly effective in relapsing-remitting MS, based on MRI results

Presented By

Prof. Yan Xu, Peking Union Medical College Hospital, China

Trial

Phase 2

Conference

ACTRIMS 2025

Type

News article

12 March 2025 10:14

Genetic and phenotypic risk model predicts MS

Presented By

Ms Alyks Linerud, Brigham Young University, UT, USA

Conference

ACTRIMS 2025

Type

News article

12 March 2025 10:12

Treatment with cladribine tablets: real-world insights

Presented By

Gerard Harty, Merck KGaA, Germany

Trial

CLADRISE

Conference

ACTRIMS 2025

Type

News article

11 March 2025 14:23

Ocrelizumab significantly reduces new/enlarging cortical lesions

Presented By

Prof. Michael Dwyer, University at Buffalo, NY, USA

Trial

Phase 3, ORATORIO

Conference

ACTRIMS 2025

Type

News article

11 March 2025 14:21

Safety of 30-minute ublituximab infusions confirmed

Presented By

Dr John Foley, Rocky Mountain Multiple Sclerosis Center, UT, USA

Trial

ENHANCE

Conference

ACTRIMS 2025

Type

News article

11 March 2025 14:20

Bempikibart shows its potential for hair regrowth in alopecia areata

Presented By

Dr Brett King, Yale Medicine, USA

Trial

Phase 2, SIGNAL-AA

Conference

AAD 2025

Type

News article

11 March 2025 10:50

Cutaneous immune-related AEs may predict toxicities in ICI-treated patients

Presented By

Elle Kim, John Hopkins University, USA

Conference

AAD 2025

Type

News article

11 March 2025 10:45

Excellent long-term data for TYK2 inhibitor ESK-001 in psoriasis

Presented By

Dr Andrew Blauvelt

Trial

Phase 2, STRIDE

Conference

AAD 2025

Type

News article

11 March 2025 10:44

Nearly all patients respond to deucravacitinib in lichen planopilaris study

Presented By

Dr Alyssa Stockard, Mayo Clinic, USA

Trial

Phase 2

Conference

AAD 2025

Type

News article

11 March 2025 10:43

Reduced biopsy rate and improved malignancy rate with high-end imaging tool

Presented By

Jordan Phillipps, Washington University School of Medicine, USA

Conference

AAD 2025

Type

News article

11 March 2025 10:41

Comorbidity burden associated with risk of adverse events

Presented By

Prof. Amber Salter, UT Southwestern Medical Center, TX, USA

Conference

ACTRIMS 2025

Type

News article

10 March 2025 16:13

A pre-relapse immune signature implicates EBV reactivation in MS relapse

Presented By

Dr Devin King, Brigham and Women’s Hospital, MA, USA

Conference

ACTRIMS 2025

Type

News article

10 March 2025 16:12

ROCKET ignites interest in rocatinlimab

Presented By

Prof. Emma Guttman, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, ROCKET-Horizon

Conference

AAD 2025

Type

News article

10 March 2025 11:46

Upadacitinib efficacy in palmoplantar pustulosis

Presented By

Prof. Yuling Shi, Tongji University School of Medicine, China

Conference

AAD 2025

Type

News article

10 March 2025 11:44

ICONIC-LEAD in plaque psoriasis

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 3, ICONIC-LEAD

Conference

AAD 2025

Type

News article

10 March 2025 11:42

A ‘TYK’ above placebo: ICP-488 in plaque psoriasis

Presented By

Dr Xiaoguang Zhang, Second Hospital of Hebei Medical University, China

Trial

Phase 2

Conference

AAD 2025

Type

News article

10 March 2025 11:40

Baricitinib regrows hair in AA adolescents

Presented By

Prof. Thierry Passeron, Nice University Hospital, France

Trial

Phase 3, BRAVE-AA-PEDS

Conference

AAD 2025

Type

News article

10 March 2025 11:39

Favourable effectiveness and persistence of cladribine versus other oral DMTs

Presented By

Prof. Helmut Butzkueven, Monash University, Australia

Trial

GLIMPSE

Conference

ACTRIMS 2025

Type

News article

5 March 2025 13:12

Immunomodulatory potential of ketogenic diet in MS confirmed

Presented By

Dr Michael Kornberg, Johns Hopkins University, MD, USA

Conference

ACTRIMS 2025

Type

News article

5 March 2025 13:11

Paramagnetic rim lesions predict effectiveness of tolebrutinib

Presented By

Dr Jiwon Oh, University of Toronto, Canada

Trial

Phase 3, GEMINI, HERCULES

Conference

ACTRIMS 2025

Type

News article

5 March 2025 13:10

Atypical and radiological-only presentations often meet 2024 MS criteria

Presented By

Ms Alexandra Scharf, Cleveland Clinic, OH, USA

Conference

ACTRIMS 2025

Type

News article

4 March 2025 12:04

Higher-dosed ocrelizumab associated with less disability accrual

Presented By

Dr Robert Bermel, Cleveland Clinic, OH, USA

Trial

Phase 3, OPERA

Conference

ACTRIMS 2025

Type

News article

4 March 2025 12:01

Update on safety profile of cladribine tablets yields positive results

Presented By

Prof. Thomas Leist, Jefferson University, PA, USA

Conference

ACTRIMS 2025

Type

News article

4 March 2025 12:00

Ofatumumab: good initial adherence and treatment satisfaction

Presented By

Dr Anneke van der Walt, Monash University, Australia

Trial

EAFToS

Conference

ACTRIMS 2025

Type

News article

4 March 2025 11:58

MS activity remains low on long-term fenebrutinib

Presented By

Prof. Amit Bar-Or, University of Pennsylvania, PA, USA

Trial

Phase 2, FENopta

Conference

ACTRIMS 2025

Type

News article

4 March 2025 11:56

GRAVITI: Solid induction and maintenance data for subcutaneous guselkumab in CD

Presented By

Prof. Ailsa Hart, London North-West University, UK

Trial

Phase 3, GRAVITI

Conference

ECCO 2025

Type

News article

26 February 2025 08:54

Higher neoplasia detection rate with virtual CE in real-world IBD study

Presented By

Dr Chandni Radia, King’s College London, UK

Conference

ECCO 2025

Type

News article

26 February 2025 08:52

Long-term use of etrasimod in UC safe and well tolerated

Presented By

Prof. Séverine Vermeire, Leuven University Hospital, Belgium

Conference

ECCO 2025

Type

News article

26 February 2025 08:49

Kono-S or side-to-side anastomosis for resection in Crohn’s terminal ileitis?

Presented By

Dr Koianka Trencheva, Cornell University, NY, USA

Conference

ECCO 2025

Type

News article

26 February 2025 08:47

Sustained efficacy and stable safety profile for risankizumab in UC

Presented By

Prof. Raja Atreya, Friedrich-Alexander University, Germany

Trial

COMMAND

Conference

ECCO 2025

Type

News article

26 February 2025 08:45

Novel TL1A inhibitor achieves high rates at stringent endpoints in UC

Presented By

Prof. Vipul Jairath, Western University, Canada

Trial

Phase 2, TUSCANY-2

Conference

ECCO 2025

Type

News article

25 February 2025 11:34

First IL-7 inhibitor for UC shows its potential

Presented By

Dr Arnaud Bourreille, Nantes University, France

Conference

ECCO 2025

Type

News article

25 February 2025 11:32

PREdiCCT: Role of psychosocial factors in IBD flares unravelled

Presented By

Dr Lauranne Derikx, Erasmus MC, the Netherlands

Trial

PREdiCCT

Conference

ECCO 2025

Type

News article

25 February 2025 11:30

Positive results for TL1A inhibitor duvakitug in CD

Presented By

Prof. Vipul Jairath, Western University, Canada

Trial

Phase 2, RELIEVE UCCD

Conference

ECCO 2025

Type

News article

25 February 2025 11:28

EFFICACI: Infliximab or vedolizumab after TNF failure in UC?

Presented By

Prof. Guillaume Bouguen, CHU Rennes, France

Trial

EFFICACI

Conference

ECCO 2025

Type

News article

25 February 2025 11:26

Could stem cell transplantation be a fruitful solution for refractory CD?

Presented By

Dr Louis Cohen, Mount Sinai, NY, USA

Conference

ECCO 2025

Type

News article

24 February 2025 11:16

VEDOKIDS: Long-term outcomes of vedolizumab in paediatric IBD

Presented By

Dr Ohad Atia, Shaare Zedek Medical Centre, Israel

Trial

VEDOKIDS

Conference

ECCO 2025

Type

News article

24 February 2025 11:13

Improving efficacy with longer mirikizumab treatment in CD

Presented By

Prof. Séverine Vermeire, KU Leuven, Belgium

Trial

VIVID-2

Conference

ECCO 2025

Type

News article

24 February 2025 11:11

Antibody responses predict IBD onset 10 years before diagnosis

Presented By

Dr Arno Bourgonje, University Medical Center Groningen, the Netherlands

Conference

ECCO 2025

Type

News article

24 February 2025 11:09

Long-term upadacitinib data reassuring for patients with UC

Presented By

Prof. Remo Panaccione, University of Calgary, Canada

Trial

U-ACTIVATE

Conference

ECCO 2025

Type

News article

24 February 2025 11:02